Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Pharmadrug CEO says completion of cGMP substance manufacturing advances its programs

Pharmadrug CEO says completion of cGMP substance manufacturing advances its programs

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) CEO Daniel Cohen joined Proactive's Stephen Gunnion with the news that the company has completed cGMP (good manufacturing practices) production of a multi-kilogram batch of cepharanthine-2HCl, a key ingredient in PD-001, the oral version of cepharanthine.

Cohen told Proactive that completion of this lot advances the company's efforts to support pre-clinical and clinical development, including the commencement of Phase 2 clinical studies, for parallel indications in oncology and infectious disease.

#ProactiveInvestors #PharmaDrug #cGMP #cepharanthine #CSE #OTCQB

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK